EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Performance of 123 I‐ioflupane SPECT striatal binding in dementia with Lewy bodies

Emily F Maly, Frank P DiFilippo, Brittany Lapin, Yadi Li, Sarah Berman, Andrea C Bozoki, Jori E Fleisher, James E Galvin, David J Irwin, Carol F Lippa, Irene Litvan, Debby W Tsuang und 6 weitere

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.70596 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Emily F Maly und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Tomography, Emission-Computed, Single-Photon, Lewy Body Disease, Nortropanes, Corpus Striatum. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Douglas Herthel DVM Memorial Fund Jane and Lee Seidman Endowed Chair for Advanced Neurological Education and Research, Amprion, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION We aimed to determine whether 123 I‐ioflupane single‐photon emission computed tomography (SPECT) striatal binding ratio (SBR) correlated with parkinsonian motor symptoms in dementia with Lewy bodies (DLB) and if SBR predicts worsening of parkinsonism over time. METHODS A retrospective cohort study of the U.S. Dementia with Lewy Bodies Consortium dataset including individuals with DLB with baseline 123 I‐ioflupane SPECT analyzed with DaTQUANT and baseline and 24‐month Movement Disorder Society Unified Parkinson's Disease Rating Scale–Part III (MDS‐UPDRS‐III). A subset had cerebrospinal fluid α‐synuclein seed amplification assay (SAA) evaluation. RESULTS Baseline mean SBRs were significant predictors of baseline and 24‐month MDS‐UPDRS‐III scores, although they did not predict meaningful worsening over time. SAA positivity was associated with lower SBRs; Z score cut‐off values are provided. DISCUSSION In suspected DLB, 123 I‐ioflupane SPECT, at diagnosis, could be used to confirm underlying dopamine deficiency; it does not predict meaningful worsening of motor parkinsonism. More severe dopamine deficiency increases confidence in presence of synucleinopathy. Highlights 123 I‐ioflupane single‐photon emission computed tomography (SPECT) can confirm underlying dopamine deficiency. Striatal binding ratio (SBR) Z scores predicted 24‐month Unified Parkinson's Disease Rating Scale–Part III (UPDRS‐III) scores. SBR Z scores are not predictive of subsequent meaningful worsening of parkinsonism. More severe dopamine dysfunction on SPECT is associated with presence of seed amplification assay (SAA). SBR Z score cut‐offs that indicate cerebrospinal fluid SAA positivity are provided.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tomography, Emission-Computed, Single-PhotonLewy Body DiseaseNortropanesCorpus StriatumHumansMaleFemaleRetrospective StudiesAgedalpha-SynucleinAged, 80 and overIodine Radioisotopes

Stichwörter der Autor:innen

123I‐ioflupane single‐photon emission computed tomographyMovement Disorder Society Unified Parkinson's Disease Rating Scale Part IIIdementia with Lewy bodiesdopamine transporter scanstriatal binding ratioα‐synuclein seed amplification assay

Substanzen

ioflupaneNortropanesalpha-SynucleinIodine Radioisotopes

Autor:innen und Institutionen

  • Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Division of Nuclear Medicine, Diagnostics Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Quantitative Health Sciences, Lerner Research Institute & Center for Outcomes Research and Evaluation, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Neurology, University of North Carolina, Chapel Hill, North Carolina, USA.

Förderung

  • Douglas Herthel DVM Memorial Fund Jane and Lee Seidman Endowed Chair for Advanced Neurological Education and Research
  • Amprion
  • NINDS NIH HHS
  • Lewy Body Dementia Association
  • NIA NIH HHS
  • GE Healthcare
  • National Institute of Neurological Disorders and Stroke
  • National Institute on Aging

Zitieren

APA

Maly, E. F., DiFilippo, F. P., Lapin, B., Li, Y., Berman, S., Bozoki, A. C., Fleisher, J. E., Galvin, J. E., Irwin, D. J., Lippa, C. F., Litvan, I., Tsuang, D. W., Zabetian, C. P., Taylor, A. S., Bekris, L. M., Lopez, O. L., Galasko, D., & Leverenz, J. B. (2025). Performance of 123 I‐ioflupane SPECT striatal binding in dementia with Lewy bodies. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70596

Vancouver

Maly EF, DiFilippo FP, Lapin B, Li Y, Berman S, Bozoki AC, et al. Performance of 123 I‐ioflupane SPECT striatal binding in dementia with Lewy bodies. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70596

BibTeX
@article{Maly2025,
  author = {Maly, Emily F and DiFilippo, Frank P and Lapin, Brittany and Li, Yadi and Berman, Sarah and Bozoki, Andrea C and Fleisher, Jori E and Galvin, James E and Irwin, David J and Lippa, Carol F and Litvan, Irene and Tsuang, Debby W and Zabetian, Cyrus P and Taylor, Angela S and Bekris, Lynn M and Lopez, Oscar L and Galasko, Douglas and Leverenz, James B},
  title = {Performance of 123 I‐ioflupane SPECT striatal binding in dementia with Lewy bodies},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.70596}
}
Kostenlos starten →